P625: A PHASE 1B/2 STUDY OF NAVTEMADLIN COMBINED WITH ACALABRUTINIB IN BTK INHIBITOR NAÏVE PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPH... von Byrd, John C., Ali Bhat, Seema, Awan, Farrukh, Giri, Pratyush, Ratnasingam, Sumita, Hájek, Roman, Hess, Dagmar, Alves, Daniela, Maciej Zaucha, Jan, Shen, Annalise, Bilotti, Elizabeth, Mcgreivy, Jesse, P. Rothbaum, Wayne, Ciepluch, Hanna

Volltext

A Phase (Ph) 2 Study of TL-895, a Highly Selective, Novel Covalent BTK Inhibitor (BTKi), in Patients (pts) with Treatment-Naïve (TN) and Relapsed/Refractory (R/R) BTKi-Naïve Chroni... von Byrd, John C., Woszczyk, Dariusz, Illes, Arpad, Jurczak, Wojciech, Chraniuk, Dominik, Giannopoulos, Krzysztof, Mikhailova, Nataliia, Illconzai, Peter, Bhat, Seema A, Romanyuk, Nataliya, Usenko, Ganna, Kuchkova, Olha, Chandler, Jason, Bilotti, Elizabeth, Shen, Annalise, Cheung, Jean, Verstovsek, Srdan, McGreivy, Jesse, Rothbaum, Wayne, Kaźmierczak, Maciej

Volltext

Navtemadlin (KRT-232) activity after failure of anti-PD-1/L1 therapy in patients (pts) with TP53 WT Merkel cell carcinoma (MCC) von Wong, Michael K.K., Burgess, Melissa Amber, Chandra, Sunandana, Schadendorf, Dirk, Silk, Ann W., Olszanski, Anthony J., Grob, Jean-Jacques, Jang, Sekwon, Grewal, Jaspreet Singh, Lewis, Karl D., Fecher, Leslie Anne, Rabinowits, Guilherme, Lebbe, Celeste, Shen, Annalise, Chan, Tiffanie, McGreivy, Jesse S., Rothbaum, Wayne P., Hanna, Glenn J., Kelly, Ciara Marie

Volltext